Pericarditis & myocarditis algorithm
One algorithm for the inflammatory myopericardial syndrome of the 2025 ESC guideline. It counts the four pericarditis criteria, adds myocardial involvement (troponin, LV function, Lake Louise CMR, biopsy) to classify acute pericarditis, myopericarditis, perimyocarditis or myocarditis, and checks the major and minor high-risk features and myocarditis complications (heart failure, shock, arrhythmia, giant-cell or checkpoint-inhibitor myocarditis). It then sets out admission, work-up (ACS exclusion, CMR, EMB), aspirin or NSAID with colchicine by weight, low-dose corticosteroids, IL-1 antagonists for recurrence, heart failure and immunosuppressive treatment, and return to exercise, with ESC 2025 beside the ACC 2024 myocarditis pathway and the ACC 2025 pericarditis guidance.
- Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J 2025;46:3952-4041.
- Drazner MH, Bozkurt B, Cooper LT, et al. 2024 ACC Expert Consensus Decision Pathway on strategies and criteria for the diagnosis and management of myocarditis. J Am Coll Cardiol 2025;85:391-431.
- 2025 ACC Concise Clinical Guidance on the diagnosis and management of pericarditis. J Am Coll Cardiol 2025.
- Adler Y, Charron P, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J 2015;36:2921-2964.
- Ferreira VM, Schulz-Menger J, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations (updated Lake Louise criteria). J Am Coll Cardiol 2018;72:3158-3176.
- Imazio M, et al. A randomized trial of colchicine for acute pericarditis (ICAP). N Engl J Med 2013;369:1522-1528.
- Klein AL, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis (RHAPSODY). N Engl J Med 2021;384:31-41.